Skip to main content
SpringerLink
Log in

Response to the Letter from Dr. Jacob Peedicayil

  • Letter to the Editor
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O'Donovan MC, Corvin A, Cichon S, Sullivan PF (2015) Evaluating historical candidate genes for schizophrenia. Mol Psychiatry 20:555–562

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hu CY, Qian ZZ, Gong FF, Lu SS, Feng F, Wu YL, Yang HY, Sun YH (2015) Methylenetetrahydrofolate reductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: an updated meta-analysis. J Neural Transm (Vienna) 122:307–320

    Article  CAS  Google Scholar 

  • Misiak B, Laczmanski L, Sloka NK, Szmida E, Piotrowski P, Loska O, Slezak R, Kiejna A, Frydecka D (2016) Metabolic dysregulation in first-episode schizophrenia patients with respect to genetic variation in one-carbon metabolism. Psychiatry Res 238:60–67

    Article  CAS  PubMed  Google Scholar 

  • Sakuma K, Matsunaga S, Nomura I, Okuya M, Kishi T, Iwata N (2018) Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. Psychopharmacology 235:2303–2314

    Article  CAS  PubMed  Google Scholar 

  • Wang W, Fan W, Shi B, Tong C, Wang X, Cai J, Zhang C (2017) Effect of MTHFR gene on the schizophrenia and its cognitive function. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 34:905–908

    PubMed  Google Scholar 

  • Yoshimi A, Aleksic B, Kawamura Y, Takahashi N, Yamada S, Usui H, Saito S, Ito Y, Iwata N, Inada T, Noda Y, Yamada K, Ozaki N (2010) Gene-wide association study between the methylenetetrahydrofolate reductase gene (MTHFR) and schizophrenia in the Japanese population, with an updated meta-analysis on currently available data. Schizophr Res 124:216–222

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Donald C. Goff (Marvin Stern Professor, Vice Chair for Research, Department of Psychiatry, NYU Langone Medical Center, NY, USA), Dr. Eric A. Macklin (MGH Biostatistics Center, Boston, MA, USA), and Dr. William M. Greenberg (St. George’s University School of Medicine, True Blue, Grenada, Mental Health Association of Rockland County, Valley Cottage, NY, USA) for providing information relevant to this study.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan

    Kenji Sakuma, Taro Kishi & Nakao Iwata

Authors
  1. Kenji Sakuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taro Kishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nakao Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The manuscript was written by all authors.

Corresponding author

Correspondence to Taro Kishi.

Ethics declarations

Conflicts of interest

Drs. Sakuma, Kishi, and Iwata declare that they have no direct conflicts of interest relevant to this study.

Dr. Sakuma has received speaker’s honoraria from Otsuka.

Dr. Kishi has received speaker’s honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, MSD, Tanabe-Mitsubishi, and Yoshitomi and has received a Health Labour Sciences Research Grant and a Fujita Health University School of Medicine research grant.

Dr. Iwata has received speaker’s honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer and has received research grants from GlaxoSmithKline, Meiji, and Otsuka.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sakuma, K., Kishi, T. & Iwata, N. Response to the Letter from Dr. Jacob Peedicayil. Psychopharmacology 236, 1403–1404 (2019). https://doi.org/10.1007/s00213-018-5143-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-018-5143-x

Search

Navigation